Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Al Razi Medical Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 7.74%.
Al Razi Medical Co (SAU:9572) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Al Razi Medical Co ROCE % Related Terms
Al Razi Medical Co ROCE % Historical Data
* Premium members only.
The historical data trend for Al Razi Medical Co's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Al Razi Medical Co (SAU:9572) has a ROCE % of 7.74% as of Dec. 2025.
Is Al Razi Medical Co's ROCE % too high?
Al Razi Medical Co's current ROCE % is 7.74%. The Healthcare Providers & Services industry median ROCE % is 6.36. Al Razi Medical Co's value of 7.74% is 21.7% above this industry median. Overall, Al Razi Medical Co has a GF Score™ of 45/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Al Razi Medical Co's ROCE % compare to competitors?
Al Razi Medical Co's ROCE % of 7.74% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.36. Al Razi Medical Co's value of 7.74% is 21.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.36, based on 643 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Al Razi Medical Co's current ROCE % of 7.74% is 21.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Al Razi Medical Co's current ROCE % is 7.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Al Razi Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Al Razi Medical Co (SAU:9572) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼64.45, compared to a current price of ﷼30.32 — trading 53% below its estimated fair value. The current ROCE % is 7.74% and 21.7% above the Healthcare Providers & Services industry median of 6.36. Al Razi Medical Co's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Al Razi Medical Co (SAU:9572), the current ROCE % is 7.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Al Razi Medical Co (SAU:9572) Overvalued in 2026?
Based on GuruFocus' analysis, Al Razi Medical Co stock appears to be undervalued.
The current stock price of ﷼30.32 is trading 53% below its estimated GF Value™ of ﷼64.45.
GuruFocus considers Al Razi Medical Co to be Significantly Undervalued.
Key valuation signals for SAU:9572:
ROCE %: 7.74%
GF Value™: ﷼64.45 vs. price of ﷼30.32 (53% below fair value)
Industry Position: 21.7% above the Healthcare Providers & Services median
No single metric tells the full story. See the SAU:9572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Al Razi Medical Co operates in the medical field in the Kingdom of Saudi Arabia. The company provides all pharmaceutical and cosmetic products. It engages in buying and selling pharmaceuticals, medical supplies, herbal and cosmetic products, and all related products on a wholesale and retail basis.
45GF Score
Get the complete analysis for SAU:9572
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9572 has been successfully added to your 
